GLP-1R has emerged as a key therapeutic target in obesity and diabetes research, inspiring the development of dual and triple receptor agonists that synergistically enhance glycemic control, promote weight loss, and improve overall metabolic health
If you have any questions about whether GLP-1 medications are covered, call your insurance provider directly and ask them
GLP-1 medications are FDA-approved for type 2 diabetes management and, at higher doses, for chronic weight management in adults with obesity or overweight with weight-related comorbidities
Trial data comparison shows the progression from single-agonist (semaglutide) to dual-agonist (tirzepatide) to triple-agonist (retatrutide) correlates with increasing weight loss efficacy
In Phase 2 studies, it led to a bigger average weight drop (about 24%) than Tirzepatide (about 21%)
Mistake 3: eating too late Eating dinner at 9 PM and going to bed at 10:30 PM is a recipe for nighttime nausea, acid reflux, and poor sleep quality